Context: Androgen deprivation therapy (ADT) remains the cornerstone of management of prostate cancer (PCa). Previous studies have shown that men undergoing ADT develop insulin resistance and diabetes, but the mechanisms behind ADT-induced metabolic abnormalities remain unclear.
, androgen withdrawal is associated with cardiometabolic adverse effects. Indeed, men undergoing ADT experience adverse changes in body composition, which leads to insulin resistance, diabetes, and increased cardiovascular morbidity and mortality (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) . Yet, the mechanisms behind the worsening of insulin sensitivity and metabolic health in these men remain unclear.
In obesity-associated insulin resistance and diabetes, the dysfunctional adipose tissue secretes several inflammatory cytokines, such TNF-a and IL-6, that are known to decrease insulin sensitivity (25, 26) . Indeed, obese men and women have higher circulating levels of C-reactive protein (CRP), IL-6, and TNF-a (27, 28) , and antagonism of IL-6 or TNF-a improves insulin sensitivity (29) (30) (31) . These observations suggest that inflammation has an important contribution to the development of insulin resistance and diabetes (25, 26) . It has been known that testosterone modulates inflammation and has anti-inflammatory properties. Population studies have shown that endogenous testosterone levels in older men are negatively associated with circulating levels of CRP, IL-6, and TNF-a (32) (33) (34) (35) . Additionally, clinical trials have shown that testosterone replacement in hypogonadal men reduces TNF-a and IL-1b, while increasing the anti-inflammatory cytokine IL-10 (36). Thus, the loss of anti-inflammatory effects of testosterone during ADT might play a role in the worsening of insulin sensitivity in these men.
Another potential mediator that might contribute to metabolic dysfunction in men undergoing ADT is adipocyte protein 2 (aP2), an adipokine also known as fatty acid-binding protein 4. aP2 is actively secreted from adipocytes and regulates hepatic glucose production and is itself regulated by fasting-and lipolysis-related signals (37) . Serum aP2 levels are higher in obese mice (37) and humans (38) . Administration of recombinant aP2 in mice increases hepatic glucose production (37) and induces insulin resistance (39) , whereas blocking aP2 with monoclonal antibodies in obese mice lowers glucose concentrations and improves insulin sensitivity (37, 40) . As low testosterone levels are associated with an increase in fat mass (41, 42) , it is conceivable that increased aP2 production from adipocytes might contribute to ADT-related metabolic dysfunction. However, serum concentrations of aP2 have not been measured in this patient population.
The Androgen Deprivation Therapy and Pain Perception (ADT and Pain) study was a prospective observational study that evaluated the impact of ADT on clinical and experimental pain in nondiabetic men with nonmetastatic PCa and compared them to nondiabetic men with localized PCa who had previously undergone prostatectomy and were in remission (control group); both cohorts had normal serum testosterone levels at baseline (43) . The present substudy was designed to evaluate the role of inflammatory cytokines and aP2 levels on ADT-induced metabolic dysfunction. The design of the study allowed us to follow participants prospectively in a systematic way and to obtain blood samples at the same time intervals in both cohorts.
Methods

Study design and participants
The ADT and Pain study was a prospective cohort study designed to evaluate changes in pain perception and tolerance in men undergoing ADT for PCa. The study design and eligibility criteria have been published previously (43) . Briefly, 37 nondiabetic men without skeletal metastasis about to undergo medical ADT with GnRH agonist [22.5 mg of leuprolide acetate (Lupron depot; TAP Pharmaceuticals)] every 3 months with a planned intervention of at least 6 months were enrolled from the Dana-Farber Cancer Institute (ADT group). All men received an androgen receptor antagonist (bicalutamide) during the first month of treatment to prevent tumor flare; half of the patients also received concurrent radiation therapy. Additionally, 40 nondiabetic men with PCa who had undergone prostatectomy and/or radiation therapy for organ-confined PCa at least 6 months prior to enrollment and were in remission served as the control group and were recruited from the Brigham and Women's Hospital (non-ADT group). All men had normal serum total testosterone concentrations at the time of enrollment. Main exclusion criteria also included use of opioidanalgesics, painful inflammatory conditions, use of glucocorticoids, and moderate to severe depression.
For the current substudy, four participants in the ADT group who did not have sufficient quantity of postbaseline blood samples were excluded from the analyses; 73 men (33 in the ADT group and 40 in the non-ADT group) formed the analytical sample.
The ADT and Pain study protocol was approved by the institutional review boards at the Dana-Farber Cancer Institute and the Brigham and Women's Hospital, Boston, Massachusetts. Enrollment took place between July 2013 and April 2016; the last participant completed the study in November 2016. All participants provided written informed consent.
Laboratory measurements
Fasting serum samples were collected in the morning at baseline and at each follow-up visit (6, 12 , and 24 weeks after enrollment).
Testosterone
Measurement of serum total testosterone levels was performed using liquid chromatography-tandem mass spectrometry (the gold-standard method) in a laboratory certified by the Centers for Disease Control. The lowest detection limit with this method was 2 ng/dL (44) .
Glucose, insulin, and insulin sensitivity
Fasting plasma glucose was quantified using Beckman Glucose Analyzer 2 (Beckman Instruments, Inc., Fullerton, CA). Fasting insulin was measured using high-sensitivity sandwich ELISA (Alpco Diagnostics, Salem, NH). Homeostatic model assessment of insulin resistance (HOMA-IR) (45) was calculated.
Cytokines CRP levels were measured using a high-sensitivity sandwich ELISA (Alpco Diagnostics, Salem, NH) with an intra-assay coefficient of variation (CV%) of 5.6%. Measurement of IL-6 was performed by chemiluminescent immunoassay (Beckman Coulter, Fullerton, CA) with limit of detection of 0.5 pg/mL, intra-assay CV% of 4.6%, and interassay CV% of 12%. TNFa was also measured using ELISA (R&D Systems, Minneapolis, MN) with limit of detection of 0.55 pg/mL, intra-assay CV% of 8.5%, and interassay CV% of 10.6%.
aP2
Measurement of aP2 was performed using a solid-phase immunoassay for human A-fatty acid-binding protein 4 (R&D Systems Minneapolis, MN), with a limit of detection of 0.625 ng/ mL, intra-assay CV% of 3.4%, and interassay CV% of 12.6%.
Lipids
Fasting triglycerides, total cholesterol, high-density lipoprotein (HDL) cholesterol, and low-density lipoprotein (LDL) cholesterol were measured by Quest Diagnostics (Cambridge, MA).
Liver function tests
As hepatic steatosis commonly co-occurs in patients with insulin resistance and metabolic syndrome (46), we also measured liver function tests. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) were measured by Quest Diagnostics (Cambridge, MA).
Statistical analysis
Baseline characteristics of participants were summarized by treatment groups using means and standard deviations.
The effect of 6-month treatment intervention was investigated using mixed-effects linear regression model, and analyses were performed on the set of participants with data available at baseline and at least at one postrandomization time point. Differences between ADT and non-ADT groups for analyzed regressions were examined using estimated average change from baseline from three available assessments at 6, 12, and 24 weeks and were extracted from mixed-model framework. Models included random intercept at the participant level to acknowledge serial correlation and fixed effects for group term (ADT vs non-ADT), visit, and the visit-by-group interaction. All tests were performed with the two-sided type 1 error of a = 0.05. Analyses were conducted using SAS 9.4 (SAS Institute, Inc., Cary, NC) and R software version 3.2.4.
Results
Seventy-three men (33 in the ADT group and 40 in the non-ADT group) from whom at least one postbaseline sera was obtained formed the analytical sample. The median age of the participants was 67 years (range: 53 to 89 years), and mean body mass index (BMI) was 28.2 kg/m 2 (range: 21.6 to 38.3 kg/m 2 ). Baseline characteristics of the participants are detailed in Table 1 .
Serum testosterone
ADT successfully suppressed testosterone production to a mean (6 SD) concentration of 13 6 8 ng/dL, whereas testosterone levels did not change in the non-ADT group (468 6 185 ng/dL; Fig. 1 ).
Anthropometry
Compared with the non-ADT group, men in the ADT group did not experience significant changes in body weight, BMI, or waist and hip circumferences. Similarly, there was no treatment-associated change in the waist-tohip ratio (Table 2) .
Glucose, insulin, and insulin sensitivity
Men receiving ADT did not experience significant changes in fasting glucose levels, which were not different compared with subjects in the non-ADT group ( Fig. 2 ; Table 2 ). However, fasting insulin concentrations significantly increased in men in the ADT group (estimated mean change = 1.0 mIU/L; 95% CI = 0 to 1.9 mIU/L; P = 0.044), whereas no change was seen in the non-ADT group (0.2 mIU/L; 95% CI = -0.6 to 1.1 mIU/L; P = 0.562). However, there was no significant treatmentassociated change in fasting insulin when comparing the ADT to the non-ADT group (estimated mean difference = 0.7 mIU/L; 95% CI = -0.6 to 2 mIU/L; P = 0.231; Fig. 2 ; Table 2 ). Mirroring these observations, HOMA-IR also increased in the ADT group (0.25; 95% CI = 0 to 0.51; P = 0.050), whereas no change was seen in the non-ADT group (0.11; 95% CI = -0.12 to 0.33; P = 0.342); however, no significant treatment effect on HOMA-IR was observed (0.14; 95% CI = -0.20 to 0.48; P = 0.401; Fig. 2 ; Table 2 ).
Inflammatory cytokines and aP2
There was no significant treatment effect in levels of CRP (-0.5 mg/L; 95% CI = -1.3 to 0.2 mg/L; P = 0.165; Fig. 3; Table 2 ) or IL-6 levels (-0.1 pg/mL; 95% CI = -1.7 to 1.5 pg/mL; P = 0.873). Interestingly, TNF-a levels slightly decreased in men on ADT (-0.1 pg/mL; 95% CI = -0.2 to 0 pg/mL; P = 0.063); this decrease was statistically significant compared with the non-ADT group (-0.2 pg/mL; 95% CI = -0.3 to -0.1 pg/mL; P = 0.004; Fig. 3 ; Table 2 ). There were no significant treatment-associated changes in serum aP2 concentrations (0.34 ng/mL; 95% CI = -3.9 to -4.6 ng/mL; P = 0.872; Fig. 3 ; Table 2 ).
Serum lipoproteins
ADT was associated with a significant increase in total cholesterol compared with men not receiving ADT (16 mg/dL; 95% CI = 9 to 23 mg/dL; P , 0.001; Fig. 4 ; Figure 1 . Changes in serum total testosterone levels in the two groups during the study (data displayed as means; error bars are 95% CI). Table 2 ). Similarly, there was a significant treatmentassociated increase in LDL levels (7 mg/dL; 95% CI = 1 to 13 mg/dL; P = 0.020; Fig. 4 ; Table 2 ). Additionally, men receiving ADT experienced a significant increase in fasting triglycerides (9 mg/dL; 95% CI = 1 to 18 mg/dL; P = 0.031), whereas no significant change was seen in the non-ADT group (3 mg/dL; 95% CI = -5 to 11 mg/dL; P = 0.426), and overall treatment effect was not significant (6 mg/dL; 95% CI = -5 to 18 mg/dL; P = 0.279; Fig. 4 ; Table 2 ). Serum levels of HDL also showed treatmentassociated increase in the ADT group (8 mg/dL; 95%CI = 5 to 10 mg/dL; P , 0.001; Fig. 4 ; Table 2 ).
Liver function tests
There was a small but statistically significant treatmentinduced increase in AST (2.2 U/L; 95% CI = 0.1 to 4.3 U/L; P = 0.039), ALT (3.1 U/L; 95% CI = 0.8 to 5.5 U/L; P = 0.010), and ALT-to-AST ratio (0.08; 95% CI = 0.01 to 0.14; P = 0.022; Fig. 4 ; Table 2 ) compared with the non-ADT group.
Discussion
PCa is the most common cancer among American men (2) , and a large number of patients with PCa receive ADT (4-6). Although ADT improves survival in a subset of patients, the profound androgen deficiency induced by this treatment is associated with several adverse effects that include sexual dysfunction, physical dysfunction, anemia, fatigue, and worsening quality of life (15, 43) . As endogenous testosterone has been shown to play a beneficial role in metabolic health in men (9-13), androgen withdrawal during ADT is associated with an increased risk of developing insulin resistance, metabolic syndrome, and diabetes, which likely contribute to the development and progression of cardiovascular disease in these men (8, (16) (17) (18) (19) (20) (21) (22) . However, the mechanisms behind ADT-induced metabolic dysfunction remain unclear. In the current study, we report that in nondiabetic men with normal serum testosterone concentrations at baseline, ADT-induced worsening of insulin sensitivity and dyslipidemia were not mediated by circulating inflammatory cytokines or aP2 levels. This underscores the need for further research to elucidate mediators of ADTinduced metabolic dysfunction.
Although treatment effect was not significant, men in the ADT group experienced worsening of insulin resistance as early as 6 weeks into treatment. Previous small uncontrolled studies had also observed a decrease in insulin sensitivity 3 to 6 months into ADT (47) (48) (49) . At baseline, the mean HOMA-IR was below the threshold considered diagnostic for insulin resistance, but the estimated change of 0.3 units observed in the ADT group might be sufficient to predispose at-risk individuals to develop impaired glucose tolerance or diabetes. The absence of ADT-related changes in circulating inflammatory cytokines suggests that metabolic dysfunction observed in androgen-deprived men may not be driven by an inflammatory process. Our observations are complimentary to a previous cross-sectional study that did not report differences in inflammatory markers among men undergoing long-term ADT (at least 12 months), age-matched men with PCa not undergoing ADT, and healthy controls without cancer (50) .
Considering the pathogenic role of adipokine aP2 in inducing insulin resistance in mice (37) (38) (39) (40) and its association with metabolic syndrome in humans (51-53), we hypothesized that an increase in this adipokine might contribute to metabolic dysregulation in this cohort. To the contrary, serum concentrations of aP2 did not increase in our cohort. Based on these observations, we posit that ADT-induced worsening of insulin sensitivity may not be mediated by this fatty acid-binding protein.
However, we cannot rule out the possibility of aP2 contributing to insulin resistance in men who undergo ADT for more than 6 months.
Androgen deprivation increased serum triglycerides as well as total and LDL cholesterol; this lipoprotein profile is commonly observed in patients with metabolic syndrome (49, 54, 55) . Androgen withdrawal also increases concentrations of HDL; however, it remains unclear if a subclass of HDL shows a preferential increase. As men undergoing ADT have an increased risk of cardiovascular morbidity (18) (19) (20) , it is conceivable that this increase is in dysfunctional HDL, which is proatherogenic (56) .
An interesting finding of the current study was the small but statistically significant increase in serum AST and ALT levels as well as ALT-to-AST ratio. These changes might be suggestive of early stages of hepatic fatty infiltration that accompanies worsening metabolic health. Indeed, ALT-to-AST ratio tracks well with insulin sensitivity and b-cell function (57), and higher ALT levels even within the normal range is an independent predictor of type 2 diabetes and nonalcoholic fatty liver disease (58, 59) . Recently, a large study using a medical database showed that men undergoing ADT are at increased risk of developing nonalcoholic fatty liver disease (60) . Future studies should investigate changes in hepatic parenchyma during ADT using state-of-the-art imaging techniques.
The current study has several strengths: (1) a prospective design allowed us to systematically follow changes in metabolic parameters; (2) enrollment of eugonadal, nondiabetic men provided a unique opportunity to determine the direct effect of testosterone suppression on inflammatory cytokines and aP2; (3) serum testosterone was measured by liquid chromatography-tandem mass spectrometry (the gold-standard method); (4) measurement of cytokines and aP2 was performed using validated assays; (5) all men received medical ADT with GnRH agonists (not orchiectomy), yielding a homogenous sample; and (6) enrollment of a non-ADT group as controls who were well matched in baseline characteristics with the ADT group.
The current study also has some limitations. This was a secondary analysis of the ADT and Pain study, which might have resulted in a lower power to detect changes in inflammatory cytokines or aP2; however; the sample size of this substudy was relatively large compared with previous studies. Furthermore, as participants enrolled in this study were nondiabetic, it is conceivable that these characteristics might have been responsible for findings that are different from metabolic observations seen in previous studies. We followed participants for 6 months into ADT; it is conceivable that a longer duration of follow-up might have provided greater insight into the pathophysiology of ADT-induced metabolic dysfunction.
Conclusions
Metabolic changes seen during the first 6 months of ADT are not associated with changes in circulating inflammatory cytokines or serum aP2 levels. These findings suggest that this early deterioration of metabolic health in men receiving ADT may be mediated by other molecular mechanisms that require further research.
